LABORATORINĖ MEDICINA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 416,574 | 468,467 | 515,986 | 576,050 | 643,158 | 684,764 | 746,323 | 792,269 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 34,204 | 38,148 | 73,085 | 73,471 | 58,461 | 77,983 | 57,091 | 73,367 |
| Equity | 193,788 | 216,716 | 279,801 | 328,272 | 361,733 | 419,715 | 451,806 | 490,174 |
| Liabilities | 21,274 | 18,250 | 17,938 | 14,248 | 31,259 | 33,026 | 26,328 | 20,511 |
| Non-current assets | 15,954 | 13,082 | 10,115 | 5,392 | 26,351 | 28,622 | 62,369 | 50,950 |
| Current assets | 197,627 | 220,346 | 286,291 | 336,025 | 361,386 | 422,640 | 411,778 | 457,870 |
| Total assets | 213,581 | 233,428 | 296,406 | 341,417 | 387,737 | 451,262 | 474,147 | 508,820 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 159,083 | 169,070 | 187,769 |
| Social insurance contributions | - | - | - | - | - | 33,725 | 35,388 | 37,172 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -6.7% | +12.5% | +10.1% | +11.6% | +11.6% | +6.5% | +9.0% | +6.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 16.0% | 16.3% | 24.7% | 21.5% | 15.1% | 17.3% | 12.0% | 14.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 17.7% | 17.6% | 26.1% | 22.4% | 16.2% | 18.6% | 12.6% | 15.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 8.2% | 8.1% | 14.2% | 12.8% | 9.1% | 11.4% | 7.6% | 9.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 65,775 | 83,905 | 96,748 | 109,724 | 122,506 | 122,645 | 144,449 | 158,454 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LABORATORINĖ MEDICINA - Social security debts
The company had no debts to Sodra
LABORATORINĖ MEDICINA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-03 | 2025-12-05 | 160.67 |
| 2025-05-03 | 2025-05-03 | 2679.89 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LABORATORINE MEDICINA, UAB (code 124635920) is a Private Limited Liability Company active in research and development in medical sciences. In 2025, the company generated revenue of EUR 792.3K and net profit of EUR 73.4K, corresponding to a profit margin of 9.3%. Revenue increased by 6.2% year on year and by 15.7% over two years, showing a steady upward trend. Profitability was positive across the period: net profit was EUR 78.0K in 2023, EUR 57.1K in 2024, and EUR 73.4K in 2025. Balance sheet indicators remained conservative. Total assets rose from EUR 451.3K in 2023 to EUR 508.8K in 2025, while equity increased from EUR 419.7K to EUR 490.2K. Liabilities were low at EUR 20.5K in 2025, and the equity ratio stood at 96.3%, with debt-to-equity at 0.04. Return on equity was 15.0%, return on assets 14.4%, and asset turnover 1.56x. With reported revenue per employee of EUR 158.5K, the company appears to operate with high productivity and a strong equity-funded balance sheet.